137 related articles for article (PubMed ID: 37500172)
41. Quantitative analysis of CDX2 protein expression improves its clinical utility as a prognostic biomarker in stage II and III colon cancer.
den Uil SH; de Wit M; Slebos RJC; Delis-van Diemen PM; Sanders J; Piersma SR; Pham TV; Coupé VMH; Bril H; Stockmann HBAC; Jimenez CR; Meijer GA; Fijneman RJA
Eur J Cancer; 2021 Feb; 144():91-100. PubMed ID: 33341450
[TBL] [Abstract][Full Text] [Related]
42. Simple classifiers for molecular subtypes of colorectal cancer.
Kim WG; Kim JY; Park DY
Arab J Gastroenterol; 2017 Dec; 18(4):191-200. PubMed ID: 29241727
[TBL] [Abstract][Full Text] [Related]
43. CDX-2 expression correlates with clinical outcomes in MSI-H metastatic colorectal cancer patients receiving immune checkpoint inhibitors.
Ziranu P; Pretta A; Pozzari M; Maccioni A; Badiali M; Fanni D; Lai E; Donisi C; Persano M; Gerosa C; Puzzoni M; Bardanzellu F; Ambu R; Pusceddu V; Dubois M; Cerrone G; Migliari M; Murgia S; Spanu D; Pretta G; Aimola V; Balconi F; Murru S; Faa G; Scartozzi M
Sci Rep; 2023 Mar; 13(1):4397. PubMed ID: 36928082
[TBL] [Abstract][Full Text] [Related]
44. The homeobox gene CDX2 in colorectal carcinoma: a genetic analysis.
Sivagnanasundaram S; Islam I; Talbot I; Drummond F; Walters JR; Edwards YH
Br J Cancer; 2001 Jan; 84(2):218-25. PubMed ID: 11161380
[TBL] [Abstract][Full Text] [Related]
45. The role of transcription factor caudal-related homeobox transcription factor 2 in colorectal cancer.
Wu CC; Hsu TW; Yeh CC; Huang HB
Tzu Chi Med J; 2020; 32(4):305-311. PubMed ID: 33163374
[TBL] [Abstract][Full Text] [Related]
46. The Diagnostic Value of Cadherin 17 and CDX2 Expression as Immunohistochemical Markers in Colorectal Adenocarcinoma.
Abouelkhair MB; Mabrouk SH; Zaki SSA; Nada OH; Hakim SA
J Gastrointest Cancer; 2021 Sep; 52(3):960-969. PubMed ID: 32929682
[TBL] [Abstract][Full Text] [Related]
47. An Analysis of Relationship Between RAS Mutations and Prognosis of Primary Tumour Resection for Metastatic Colorectal Cancer Patients.
Liang L; Tian J; Yu Y; Wang Z; Peng K; Liu R; Wang Y; Xu X; Li H; Zhuang R; Cui Y; Zhu C; Liu T
Cell Physiol Biochem; 2018; 50(2):768-782. PubMed ID: 30308491
[TBL] [Abstract][Full Text] [Related]
48. Methylation of CDX2 as a Predictor in Poor Clinical Outcome of Patients with Colorectal Cancer.
Jiang G; Luo C; Sun M; Zhao Z; Li W; Chen K; Fan T
Genet Test Mol Biomarkers; 2016 Nov; 20(11):710-714. PubMed ID: 27754705
[TBL] [Abstract][Full Text] [Related]
49. The clinical perspectives of CDX2 expression in colorectal cancer: a qualitative systematic review.
Olsen J; Espersen ML; Jess P; Kirkeby LT; Troelsen JT
Surg Oncol; 2014 Sep; 23(3):167-76. PubMed ID: 25126956
[TBL] [Abstract][Full Text] [Related]
50. Reduced CDX2 expression predicts poor overall survival in patients with colorectal cancer.
Hong KD; Lee D; Lee Y; Lee SI; Moon HY
Am Surg; 2013 Apr; 79(4):353-60. PubMed ID: 23574843
[TBL] [Abstract][Full Text] [Related]
51. The role of primary tumor resection in patients with stage IV colorectal cancer with unresectable metastases.
Urvay S; Eren T; Civelek B; Kilickap S; Yetiysigit T; Ozaslan E
J BUON; 2020; 25(2):939-944. PubMed ID: 32521889
[TBL] [Abstract][Full Text] [Related]
52. Transcriptome of sessile serrated adenoma/polyps is associated with MSI-high colorectal cancer and decreased expression of CDX2.
Ohki D; Yamamichi N; Sakaguchi Y; Takahashi Y; Kageyama-Yahara N; Yamamichi M; Takeuchi C; Tsuji Y; Sakai Y; Sakurai K; Tomida S; Koike K; Fujishiro M
Cancer Med; 2022 Dec; 11(24):5066-5078. PubMed ID: 35535692
[TBL] [Abstract][Full Text] [Related]
53. Prognostic significance of beta-catenin in colorectal cancer with liver metastasis.
Han SA; Chun H; Park CM; Kang SJ; Kim SH; Sohn D; Yun SH; Lee WY
Clin Oncol (R Coll Radiol); 2006 Dec; 18(10):761-7. PubMed ID: 17168211
[TBL] [Abstract][Full Text] [Related]
54. Immunohistochemical expression of CDX2, β-catenin, and TP53 in inflammatory bowel disease-associated colorectal cancer.
Laurent C; Svrcek M; Flejou JF; Chenard MP; Duclos B; Freund JN; Reimund JM
Inflamm Bowel Dis; 2011 Jan; 17(1):232-40. PubMed ID: 20815042
[TBL] [Abstract][Full Text] [Related]
55. Decreased mean platelet volume predicts poor prognosis in metastatic colorectal cancer patients treated with first-line chemotherapy: results from mCRC biomarker study.
Chang J; Lin G; Ye M; Tong D; Zhao J; Zhu D; Yu Q; Zhang W; Li W
BMC Cancer; 2019 Jan; 19(1):15. PubMed ID: 30612568
[TBL] [Abstract][Full Text] [Related]
56. Inflammation-based prognostic scores and nutritional prognostic index in patients with locally-advanced unresectable colorectal cancer.
Ikeguchi M; Urushibara S; Shimoda R; Yamamoto M; Maeta Y; Ashida K
World J Surg Oncol; 2014 Jul; 12():210. PubMed ID: 25022764
[TBL] [Abstract][Full Text] [Related]
57. [Expression of Cdx2 protein in colorectal cancer].
Pack JH; Kim TD; Oh HA; Lee EJ; Kim JW; Jang BI; Kim TN; Jung MK; Bae YK
Korean J Gastroenterol; 2005 Sep; 46(3):204-10. PubMed ID: 16179840
[TBL] [Abstract][Full Text] [Related]
58. LIN28B induces a differentiation program through CDX2 in colon cancer.
Suzuki K; Masuike Y; Mizuno R; Sachdeva UM; Chatterji P; Andres SF; Sun W; Klein-Szanto AJ; Besharati S; Remotti HE; Verzi MP; Rustgi AK
JCI Insight; 2021 May; 6(9):. PubMed ID: 33755595
[TBL] [Abstract][Full Text] [Related]
59. [Prognostic factors of patients with unresectable liver metastasis from colorectal cancer after failed conversion chemotherapy].
He H; Shen W; Chen W; Liu H; Gong W; Fu J; Hu X; Cui L
Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Nov; 21(11):1261-1267. PubMed ID: 30506537
[TBL] [Abstract][Full Text] [Related]
60. Expression of the intestinal marker Cdx2 in secondary adenocarcinomas of the colorectum.
Groisman GM; Bernheim J; Halpern M; Brazowsky E; Meir A
Arch Pathol Lab Med; 2005 Jul; 129(7):920-3. PubMed ID: 15974817
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
